COMMUNIQUÉS West-GlobeNewswire

Applied Biologics Announces Successful Manufacture of First Research Construct for Disease-Modifying Osteoarthritis Gene Therapy Program
14/07/2026
SCOTTSDALE, Ariz., July 14, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
TAP Sleep Care Highlights Breakthrough Case Study on myTAP® Oral Appliance in Journal of Dental Sleep Medicine: Dramatic Two-Night Improvement in Treatment-Resistant OSA
14/07/2026
DALLAS, July 14, 2026 (GLOBE NEWSWIRE) -- TAP Sleep Care ® , a leader in innovative oral appliance therapy for snoring and obstructive sleep apnea (OSA), today announced the publication of a compelling case report [...]
AscellaHealth Named ACAP Preferred Vendor to Advance Specialty Pharmacy Strategy, Cost Containment and Care Management
14/07/2026
BERWYN, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces it has been named as a Preferred Vendor [...]
IBA – Information Réglementée
14/07/2026
Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et [...]
SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
14/07/2026
Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding [...]
Smile Doctors Outpaces First-Half Growth Plan, Nears 600 Locations Nationwide
14/07/2026
Entering its second decade, the nation's largest ortho-focused support organization posts double-digit first-half growth as new orthodontist affiliations, de novo expansion and accelerating adult demand continue to [...]
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
14/07/2026
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America - - Dr. [...]
Visory Health Wins a Digital Health Award for Second Consecutive Year
14/07/2026
The win recognizes the app for its real-time pricing and digital Rx savings card, which help users cut prescription costs by up to 80% - no insurance or coupons required ESTERO, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- [...]
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
14/07/2026
Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents SARASOTA, FLA., July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or [...]
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
14/07/2026
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No [...]
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
14/07/2026
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor, [...]
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
14/07/2026
Conexeu Sciences is aiming CXU™ at the largest unclaimed frontier in injectable aesthetics: restoring body fullness at a scale today's fillers were never built to reach. The move builds on the company's completed 12- [...]
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia
14/07/2026
Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo. The LiBBY study [...]
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
14/07/2026
Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT 2C ) pharmacodynamics approved in its FDA product labeling. Qelbree has [...]
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
14/07/2026
WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension [...]
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
14/07/2026
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
SS Innovations Appoints Sarah M. Romano as Chief Financial Officer
14/07/2026
Veteran medtech finance executive brings extensive public company and capital markets experience to support the Company's next phase of global growth FORT LAUDERDALE, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- via IBN -- [...]
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
14/07/2026
Through a series of investments over the past year, including an additional investment made in June 2026, Weinstein has built an ownership position of more than 30% as Pluri advances its longevity and U.S. [...]
Adneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance Cebranopadol in Greater China
14/07/2026
Agreement Grants Conba Rights for the Development and Commercialization of Cebranopadol for Pain Across Mainland China, Hong Kong, Macao and Taiwan, representing an important step in expanding the global potential of [...]

Pages